NCT00043979: Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas |
|
|
| Completed | 2 | 60 | US | F-18 Fluorodeoxyglucose, FDG, therapeutic allogeneic lymphocytes, cyclophosphamide, Cytoxan, cyclosporine, Sandimmune, doxorubicin hydrochloride, Adriamycin, etoposide, Vepesid, fludarabine phosphate, Fludara, melphalan, Alkeran, prednisone, Deltasone, sirolimus, Rapamune, tacrolimus, Prograf, vincristine sulfate, Oncovin, peripheral blood stem cell transplantation, PBSCT, Filgrastim, Peripheral Blood Stem Cell donation | National Cancer Institute (NCI) | Sarcoma | 05/09 | 12/11 | | |
NCT00186628: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD |
|
|
| Completed | 2 | 36 | US | Total lymphoid irradiation, TLI, Rituximab, Rituxan, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, CSP, Sandimmune, Mycophenylate mofetil, MMF, CellCept, Filgrastim, G-CSF, Granulocyte-colony stimulating factor, Neupogen, Granisetron, Sancuso, Solumedrol, Medrol, Depo-Medrol, A-Methapred, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Hydrocortisone, Westcort | Stanford University, The Leukemia and Lymphoma Society, National Cancer Institute (NCI) | Leukemia, Mast-Cell, Mantle-cell Lymphoma | 11/10 | 12/10 | | |
